MK 1029
Alternative Names: MK1029Latest Information Update: 05 Nov 2023
At a glance
- Originator Merck Sharp & Dohme
- Class Antiallergics; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic asthma; Asthma
Most Recent Events
- 31 Dec 2017 Discontinued - Phase-I for Allergic asthma in United Kingdom (PO)
- 30 Aug 2017 Merck Sharp & Dohme completes a phase II trial for Asthma in Japan, Malaysia, Poland, South Africa and Guatemala (NCT02720081)
- 22 Mar 2016 Merck Sharp & Dohme plans a phase II trial for Asthma in USA (PO) (NCT02720081)